Business Development [Licensing]

OrphageniX holds the dominant IP portfolio for Targeted Gene Alteration including five issued patents and eight pending applications. The IP provides strong support for the commercialization of the Company’s products covering compositions and methods for utilizing single stranded oligonucleotides to induce single point alterations (corrections) in the genome, including the treatment of human diseases.

OrphageniX is actively pursuing partnerships to accelerate the development and commercialization of selected pipeline products.

For more information about partnering, please contact:

Michael Herr
267-334-5153
mherr@orphagenix.com